✦ LIBER ✦

Therapy of acute hepatitis C

✍ Scribed by Professor Alfredo Alberti; Silvia Boccato; Alessandro Vario; Luisa Benvegnù

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 679 KB
Volume: 36
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840360725

No coin nor oath required. For personal study only.

✦ Synopsis

Acute hepatitis C has a high propensity to become chronic, which provides the rationale for treating patients with acute disease attempting to prevent chronicity. Almost all published studies on therapy of acute hepatitis C have been small in size, uncontrolled, and highly heterogeneous as to patient features, dose and duration of treatment, follow-up evaluation, and criteria used to define efficacy and safety. The published studies on treatment of acute

📜 SIMILAR VOLUMES

Long-term follow-up after successful int

Long-term follow-up after successful interferon therapy of acute hepatitis C

✍ Johannes Wiegand; Elmar Jäckel; Markus Cornberg; Holger Hinrichsen; Manfred Diet 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Early treatment of acute hepatitis C infection with interferon alfa-2b (IFN -␣-2b) prevents chronicity in almost all patients. So far, no data are available on the long-term outcome after interferon (IFN) therapy of acute hepatitis C. The aim of this study was to assess the clinical, virologica

Therapy of acute hepatitis C with interf

Therapy of acute hepatitis C with interferon: How good is it really?

✍ Jorge J. Gumucio; Jorge Rakela; David D. Douglas 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

To test whether interferon can prevent acute non-A, non-B hepatitis from becoming chronic, a prospective controlled trial was conducted in 26 patients; 11 were treated for an average of 30 days with a mean of 52 megaunits of interferon and 14 acted as controls. 4 patients in the treatment group who

Duration of peginterferon therapy in acu

Duration of peginterferon therapy in acute hepatitis C: A randomized trial

✍ Sanaa M. Kamal; Khairy N. Moustafa; Jason Chen; Jutta Fehr; Azza Abdel Moneim; K 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 342 KB 👁 1 views

Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, and chronic evolution of the disease occurs in a majority of cases. To assess the efficacy and safety of peginterferon alpha-2b administered for 8, 12, or 24 weeks in patients with acute hepatitis C virus infection a to

Interferon treatment of chronic active h

Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia

✍ Waldron, Peter 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

Due to concerns that antineoplastic therapy produces prolonged decrease in immune function, interferon treatment of chronic active hepatitis C (CAHC) has been used only at one year or longer after the end of cancer therapy. We report the experience of an 11-year-old who developed symptomatic CAHC at

Therapy of hepatitis C: Overview

✍ K L Lindsay 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Based on the first decade of research on alpha interferon and improving hepatic histology. The discovery and characterization of the hepatitis C virus (HCV) led to reanalysis of in viral hepatitis, one can conclude that up to 40% of patients with compensated chronic hepatitis C and elevated alanine

Optimal therapy of hepatitis C

✍ Adrian M. Di Bisceglie; Jay H. Hoofnagle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 745 KB

The highest response rates to antiviral therapy for the treatment of chronic hepatitis C have been achieved using the combination of peginterferon and ribavirin. Recently completed controlled trials have reported rates of sustained virological response (SVR) between 50% and 60% in patients treated w